FEATURED NEWS
NEWS: EXPLORING MECHANISMS OF LIPID NANOPARTICLE-MUCUS INTERACTIONS IN HEALTHY AND CYSTIC FIBROSIS CONDITIONS (APR 2024)
Congratulations to Ying Tam, Paulo Lin and Molly Sung, co-authors of a recent article featured in PubMed. They collaborated with scientists from UBC on fundamental mechanisms of LNP-mucus interactions and rational design criteria for mucus-penetrating LNPs yielding efficient transmucosal delivery of genetic cargo into the lungs. Click to read more info.
NEWS: ACUITAS NAMED ONE OF CANADA’S TOP SMALL & MEDIUM EMPLOYERS (APR 2024)
Acuitas Therapeutics has been named one of Canada’s Top Small & Medium Employers for 2024 by the editors of Canada’s Top 100 Employers. The foundation of our success is a positive work culture where everyone feels respected, heard and valued. Our scientific innovation attracts exceptional talent, and our connected and collaborative culture retains them. Click to read the news release, the announcement and an article in The Globe and Mail.
NEWS: TARGETING LIPID NANOPARTICLES TO THE BLOOD-BRAIN BARRIER TO AMELIORATE ACUTE ISCHEMIC STROKE (MAR 2024)
Congratulations to Ying Tam and Barb Mui, co-authors of a recent article featured in Molecular Therapy. They collaborated with scientists from the University of Pennsylvania developing targeted nanomedicine to increase drug concentrations in endothelial cells of the blood-brain barrier of the injured brain for treatment of acute ischemic stroke. Click to read more info.